Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
MORE►
Daniel Siegwart
Daniel Siegwart, Ph.D., is Director of the Program in Genetic Drug Engineering, Professor of Biomedical Engineering and Biochemistry, and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. [Photo: UT Southwestern]
UT Southwestern Collaborates With Pfizer to Develop Better RNA Delivery Tech
by Lance Murray | Feb 13, 2024
UT Southwestern Medical Center and pharmaceutical company Pfizer have teamed up to develop new ways to deliver genetic treatments to patients.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
by Kevin Cummings |
Jun 29, 2022
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases.
With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
MORE►
